134 related articles for article (PubMed ID: 34782810)
1. [Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).].
Jommi C; Armeni P; Costa F; Alberti C; Bandello F; Bordonaro R; Caprodossi A; Di Maio M; Gaudioso A; Giuliani G; Langella R; Marata AM; Patarnello F; Pinto C; Rasi G; Villa F
Recenti Prog Med; 2021 Nov; 112(11):749-756. PubMed ID: 34782810
[TBL] [Abstract][Full Text] [Related]
2. Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future.
Pauwels K; Huys I; Vogler S; Casteels M; Simoens S
Front Pharmacol; 2017; 8():171. PubMed ID: 28420990
[No Abstract] [Full Text] [Related]
3. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
4. Price and reimbursement for orphan medicines and managed entry agreements: does Italy need a framework?
Jommi C; Addis A; Martini N; Nicod E; Pani M; Scopinaro A; Vogler S
Glob Reg Health Technol Assess; 2021; 8():114-119. PubMed ID: 36627869
[TBL] [Abstract][Full Text] [Related]
5. Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case.
Tarantola A; Otto MH; Armeni P; Costa F; Malandrini F; Jommi C
J Pharm Policy Pract; 2023 May; 16(1):67. PubMed ID: 37198599
[TBL] [Abstract][Full Text] [Related]
6. Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries.
Efthymiadou O; Kanavos P
BMC Health Serv Res; 2022 Aug; 22(1):1066. PubMed ID: 35987627
[TBL] [Abstract][Full Text] [Related]
7. The impact of managed entry agreements on pharmaceutical prices.
Gamba S; Pertile P; Vogler S
Health Econ; 2020 Oct; 29 Suppl 1():47-62. PubMed ID: 32628324
[TBL] [Abstract][Full Text] [Related]
8. Managed entry agreements for pharmaceuticals in Australia.
Vitry A; Roughead E
Health Policy; 2014 Sep; 117(3):345-52. PubMed ID: 24957419
[TBL] [Abstract][Full Text] [Related]
9. A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems.
Xoxi E; Rumi F; Kanavos P; Dauben HP; Gutierrez-Ibarluzea I; Wong O; Rasi G; Cicchetti A
Front Med Technol; 2022; 4():888404. PubMed ID: 35782579
[TBL] [Abstract][Full Text] [Related]
10. Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.
Trotta F; Guerrizio MA; Di Filippo A; Cangini A
JAMA Health Forum; 2023 Dec; 4(12):e234611. PubMed ID: 38153808
[TBL] [Abstract][Full Text] [Related]
11. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
Villa F; Tutone M; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G; Jommi C
Health Policy; 2019 Jun; 123(6):595-600. PubMed ID: 31097207
[TBL] [Abstract][Full Text] [Related]
12. [Establishing the value of new drugs in Italy.].
Villa F; Jommi C; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G
Recenti Prog Med; 2020 Feb; 111(2):65-69. PubMed ID: 32089554
[TBL] [Abstract][Full Text] [Related]
13. Managed Entry Agreements for Pharmaceutical Products in Middle East and North African Countries: Payer and Manufacturer Experience and Outlook.
Maskineh C; Nasser SC
Value Health Reg Issues; 2018 Sep; 16():33-38. PubMed ID: 29936067
[TBL] [Abstract][Full Text] [Related]
14. CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA.
Robinson MF; Mihalopoulos C; Merlin T; Roughead E
Int J Technol Assess Health Care; 2018 Jan; 34(1):46-55. PubMed ID: 29277174
[TBL] [Abstract][Full Text] [Related]
15. Risk sharing in managed entry agreements-A review of the Swedish experience.
Andersson E; Svensson J; Persson U; Lindgren P
Health Policy; 2020 Apr; 124(4):404-410. PubMed ID: 32093981
[TBL] [Abstract][Full Text] [Related]
16. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.
Ferrario A; Kanavos P
Soc Sci Med; 2015 Jan; 124():39-47. PubMed ID: 25461860
[TBL] [Abstract][Full Text] [Related]
17. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
[TBL] [Abstract][Full Text] [Related]
18. Australian managed entry scheme: a new manageable process for the reimbursement of new medicines?
Wonder M; Backhouse ME; Sullivan SD
Value Health; 2012 May; 15(3):586-90. PubMed ID: 22583471
[TBL] [Abstract][Full Text] [Related]
19. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
Grimm SE; Strong M; Brennan A; Wailoo AJ
Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
[TBL] [Abstract][Full Text] [Related]
20. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.
Xoxi E; Facey KM; Cicchetti A
Front Pharmacol; 2021; 12():699466. PubMed ID: 34456724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]